Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company focused on oncology drug development. The company’s research pipeline, which includes multiple drug candidates for highly resistant cancers, relies on animal testing as a standard component of preclinical and clinical-stage development. Public filings and company announcements reference the completion of preclinical laboratory tests and animal studies as integral steps in its research process.

For example, in September 2022, the company announced its WP1096 molecule would be evaluated in National Institute of Allergy and Infectious Diseases (NIAID)-funded animal studies for antiviral activity. In 2020, the company publicly launched an animal study for a drug candidate, with data expected later that year. The company’s regulatory disclosures explicitly state that concurrent with human clinical trials, it usually completes additional animal studies. This establishes animal testing as a fundamental and ongoing part of its product development and regulatory compliance strategy.